
HETEROCYCLES, Vol. 63, No. 5, 2004, pp. 1193 - 1220 Received, 10th October, 2003, Accepted, 5th February, 2004, Published online, 16th February, 2004 SYNTHESIS OF HETEROCYCLIC COMPOUNDS FROM THE REACTIONS OF DEHYDROACETIC ACID (DHA) AND ITS DERIVATIVES

Om Prakash,\* Ajay Kumar, and Shiv P. Singh

<sup>\*</sup>Department of Chemistry, Kurukshetra University, Kurukshetra, Haryana, India-136 119 Fax: 01744-238628, 238277 e-mail: chem@granth.kuk.ernet.in shivpsingh@rediffmail.com

**Abstract**-3-Acetyl-4-hydroxy-6-methyl-2-oxo-2*H*-pyran (Dehydroacetic acid, DHA) and its simple derivatives such as 3-cinnamoyl-4-hydroxy-6-methyl-2-oxo-2*H*-pyrans (Chalcone analogues of DHA) find interesting applications in the synthesis of various heterocyclic compounds. The review highlighting this aspect covers literature up to 2003.

3-Acetyl-4-hydroxy-6-methyl-2-oxo-2*H*-pyran (Dehydroacetic acid abbreviated as DHA) has been isolated from natural sources<sup>1,2</sup> and is also industrially utilizing a number of synthetic procedures. <sup>3-6</sup> The reactions of DHA and its derivatives have been shown to have a wide utility in organic synthesis. These developments along with the studies on related pyrone derivatives have been reviewed.<sup>7</sup>




Since DHA has several reactive sites, the molecule is susceptible to attack by the nucleophilic and electrophilic reagents. A nucleophile can, in principle, attack the carbonyl of the acetyl side chain located at 3-position, the carbon atom terminating the conjugated carbon chain at 6-position, the lactone carbonyl at 2-position and the carbonyl carbon at 4-position of the molecule. On the other hand, an electrophile can attack either at C(3) or C(5).

As part of our investigations dealing with the synthesis and mechanistic studies of heterocyclic compounds, we have reported some useful transformations of DHA and its derivatives.<sup>8-10</sup> A literature


survey reveals that the reactions of DHA and its derivatives with different reagents can provide a versatile route to the synthesis of a wide variety of heterocyclic compounds. The present review aims at outlining the important reactions, which lead to the formation of 5-, 6- and 7-membered heterocyclic compounds involving DHA and its derivatives. The subject matter has been divided into three major Sections I, II and III. The first Section deals with the reactions that do not involve pyrone ring of DHA, whereas the second Section describes the reactions involving the pyrone moiety leading to the formation of heterocyclic compounds. In the third Section, two important miscellaneous examples of synthesis of heterocyclic compounds are summarized. Further divisions of these Sections are based on the size/types of the heterocyclic compounds whose synthesis has been achieved with these substrates.

### SECTION I: REACTIONS THAT DO NOT INVOLVE PYRONE MOIETY

Synthesis of heterocyclic compounds while retaining the pyrone moiety of DHA has been accomplished either from DHA itself or its derivatives. A general case of transformation of DHA into a heterocyclic compound is outlined in equation **I**. The first step involves formation of intermediates by the nucleophilic attack of  $NH_2XH$  on the carbonyl of  $-COCH_3$  giving the product (2). The ring closure subsequently occurs with the formation of C(4)—X bond, the type (3).




In the second category,  $COCH_3$  group is modified into groups such as COCH:CHR (4) or  $-COCH_2X$  (5) and then further reactions take place *via* these new functionalities present at C(3).



#### A) FIVE-MEMBERED HETEROCYCLIC COMPOUNDS


#### i) Pyranopyrroles

Treatment of DHA (1) and its derivatives (prepared by the action of phosphorus pentachloride on DHA) with ethyl glycinate in boiling ethanol gives ethyl *N*- $\alpha$ -ethylidine- $\alpha$ -(4-hydroxy-6-methyl-2-oxo-3-pyranyl)glycinate (6) which undergoes condensation with aromatic amines to give 1-(*N*-arylcarbamoyl)-1,4-dihydro-3,6-dimethyl-4-oxopyrano[3,4-*c*]pyrroles (7).<sup>11</sup>



#### ii) Pyranopyrazoles

Cyclization of DHA *N*-substituted hydrazones (9) is known to furnish 1-substituted 3,6dimethylpyrano[4,3-*c*]pyrazol-4(1*H*)-ones (10).<sup>11,12</sup> However, the reaction is not straight forward as varying amounts of side products such as N,N'-disubstituted 5-hydroxy-3-methyl-4-(3-methyl-1*H*pyrazol-5-yl)-1*H*-pyrazoles are also formed. Cantos *et al*.<sup>13,14</sup> reported that the same pyranopyrazoles (10) can also be obtained regioselectively without any side reactions from *N*-alkylhydrazines and 4chloro-3-(1-chlorovinyl)-6-methyl-2-oxo-2*H*-pyran (8), while *N*-arylhydrazines give the corresponding 2-aryl-3,6-dimethylpyrano[4,3-*c*]pyrazol-4(2*H*)-ones (11). NMR (NOE) methods including long-range selective heteronuclear <sup>13</sup>C {<sup>1</sup>H} NOE enhancement measurements, allowed unambiguous distinction between -4(1H)-ones and -4(2H)-ones.




9a, R=Alkyl9b, R=Aryl and Heteroaryl

10, R	Yield	11, R	Yield
CH <sub>3</sub>	40	$C_6H_5$	53
CH <sub>2</sub> CH <sub>2</sub> OH	81	$4-ClC_6H_4$	83
Н	21	$4-CH_3C_6H_4$	58
		2-Pyridyl	33
		$3-CF_3C_6H_4$	76

# iii) Pyranylpyrazolines

Reaction of DHA with aromatic aldehydes yields 3-cinnamoyl-4-hydroxy-6-methyl-2-oxo-2*H*-pyrans<sup>15-17</sup> (**12**) which on treatment with arylhydrazines (Ar'NHNH<sub>2</sub>) in C<sub>2</sub>H<sub>5</sub>OH-CH<sub>3</sub>CO<sub>2</sub>H give the 1,5-diphenyl-3-(4-hydroxy-6-methyl-2-oxo-2*H*-pyran-3-yl)-2-pyrazolines (**13**).<sup>18-20</sup> Some of these compounds have shown significant antifungal activity against the blast fungus of the rice plant *Pyricularia oryzae*.<sup>21</sup> The same approach is effective for the synthesis of 1,5-diphenyl-3-(5-bromo-4-hydroxy-6-methyl-2-oxo-2*H*-pyran-3-yl)-2-pyrazolines (**14**, X = Br).<sup>22</sup>




Ar				
$\begin{array}{c c} OH & N \longrightarrow N \\ V &   &   &   \end{array}$	X	Ar	Ar	Yield
Ar	Br	C <sub>6</sub> H <sub>5</sub> , 4-OH-3-OCH <sub>3</sub> C <sub>6</sub> H <sub>3</sub> , 2-OHC <sub>6</sub> H <sub>4</sub>	C <sub>6</sub> H <sub>5</sub>	25-30
CH <sub>3</sub> O O	Br	C <sub>6</sub> H <sub>5</sub> , 4-OH-3-OCH <sub>3</sub> C <sub>6</sub> H <sub>3</sub> , 2-OHC <sub>6</sub> H <sub>4</sub>	$4-NO_2C_6H_4$	25-30
$CH_3  O  O$	Br	$C_6H_5$ , 4-OH-3-OCH <sub>3</sub> $C_6H_3$ , 2-OHC <sub>6</sub> $H_4$	$2,4-(NO_2)_2C_6H_3$	30-35
<b>13</b> $(X = H)$ <b>14</b> $(X = Pr)$	Н	C <sub>6</sub> H <sub>5</sub> , 4-CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub> , 4-ClC <sub>6</sub> H <sub>4</sub>	$C_6H_5$	75-80
<b>14</b> (X = Br)	Н	2-thienyl, 2-furyl, 4-pyridyl	C <sub>6</sub> H <sub>5</sub>	75-80

## iv) Pyranylpyrazoles

DHA on condensation with *N*,*N*-dimethylformamide dimethylacetal generates 4-hydroxy-6-methyl-2oxo-3-[3-dimethylaminoacryloyl]-2*H*-pyran (**15**), which on treatment with NH<sub>2</sub>NH<sub>2</sub>.2H<sub>2</sub>O leads to the cyclization, thereby producing 3-[4-hydroxy-6-methyl-2-oxo-2*H*-pyran-3-yl]pyrazole (**16**).<sup>23</sup>


1




4-Formyl-3-(4-hydroxy-6-methyl-2-oxo-2*H*-pyran-3-yl)-1-arylpyrazoles (17) have been synthesized from 9b using Vilsmeier-Haack reagent.<sup>24</sup>

		Ar	Ar	Yield
		N—NOH	C <sub>6</sub> H <sub>5</sub>	58
	2.2 equivalent DMF, POCl <sub>3</sub>		$4-CH_3C_6H_4$	55
9b	stir, 5 h	CHO	$4-ClC_6H_4$	52
	55-60 C	0 <sup>22</sup> 0 <sup>2</sup> CH <sub>3</sub>	$4-NO_2C_6H_4$	60
		17	$2,4-(NO_2)_2 C_6 H_3$	50

In a most recent development from our laboratory, it has been found that it is possible to synthesize the intermediates (18) by using 1.1 equivalent of  $POCl_3/DMF$ .<sup>24</sup>




When cyclization of the hydrazones is carried out under the normal conditions of Vilsmeier-Haack reaction i.e. by stirring the mixture (2.2 equivalent of  $POCl_3/DMF$ ) at 55-60°C for 4-5 h, the reaction gives the expected 4-formyl analogue (17). Alternatively, the products (17) have been obtained by the formylation of 18 with 1.1 equivalent of Vilsmeier-Haack reagent.




Ar	Yield	Ar	Yield
C <sub>6</sub> H <sub>5</sub>	58	$4-CH_3C_6H_4$	55
$4-ClC_6H_4$	52	$4-NO_2C_6H_4$	60
2,4-(NO <sub>2</sub> ) <sub>2</sub> C <sub>6</sub> H <sub>3</sub>	50		

Oxidation of pyranylpyrazolines (13) as described in subsection iii, using the oxidizing agent iodobenzene diacetate (IBD) in dichloromethane affords 1,5-diaryl-3-(4-hydroxy-6-methyl-2-oxo-2H-pyran-3-yl)-2-pyrazoles (19).<sup>24</sup>



### v) Pyranylthiadiazolines

Thiosemicarbazone of DHA (**20**) can be transformed into 2-(N-acylphenyl)-4-(N-acyl)-5-methyl-5-(4-acetoxy-6-methyl-2-oxo-2*H*-pyran-3-yl)thiadiazolines (**21**) on treatment with acetic anhydride and triethylamine.<sup>25</sup>




### B) SIX-MEMBERED HETEROCYCLIC COMPOUNDS


## i) Pyranopyrans

The preparation of pyranopyrans is significant both from synthetic as well as biological point of view. Several methods are available for the synthesis of 2-alkyl-7-methyl-4*H*,5*H*-pyrano[4,3-*b*]pyran-4,5-


diones of the type (22).<sup>26</sup> These methods are based on two different approaches. The first approach involves dehydrogenation of 2,3-dihydro-2-alkyl-7-methyl-4*H*,5*H*-pyrano[4,3-*b*]pyran-4,5-diones (22, flavanone analogues of DHA) by using oxidizing agents such as lead tetraacetate. The flavanones analogues (22) are prepared by the condensation of aliphatic aldehydes with DHA in the presence of piperidine. Interestingly the method is also applicable to the synthesis of 2-fluorinated alkyl analogues.




In the second approach, treatment of DHA (1) with esters  $RCO_2C_2H_5$  in the presence of LiH in THF, affords  $\beta$ -diketones of the type 3-acetoacetyl-4-hydroxy-6-methyl-2-oxo-2*H*-pyran (23).<sup>27</sup> Subsequent cyclization of 23 in the presence of conc. H<sub>2</sub>SO<sub>4</sub> results in the formation of 2-substituted 7-methylpyrano[4,3-*b*]-4*H*,5*H*-diones (24). Due to the difficulties encountered in the preparation of 2-aryl analogues of 22, the synthetic strategy for the synthesis of corresponding 24 follows different approach.



Condensation of DHA with ethyl acetoacetate in the presence of piperidine gives 3-acetyl-4,7dimethylpyrano[4,3-b]pyran-2H,5H-dione (**25**).<sup>11</sup>



Treatment of DHA with ethyl acetate and sodium methoxide in benzene affords  $\gamma$ -pyrone derivative i.e., 2,7-dimethylpyrano[4,3-*b*]pyran-4*H*,5*H*-dione (**26**).<sup>28</sup>




As compared to 2-alkyl substituted derivatives of the type (24), methods for the synthesis of 2-aryl analogues are limited. The main reason for this appears to be the failure of several attempts for the cyclization of 3-cinnamoyl-4-hydroxy-6-methyl-2-oxo-2*H*-pyrans (12) to furnish 2-aryl analogues of 24 *via* Michael-type addition. This problem has been overcome by converting 12 into the corresponding dibromo derivatives (27) in excellent yields. These bromo derivatives (27) on heating with pyridine containing a few drops of piperidine give 2-aryl-7-methylpyrano[4,3-*b*]pyran-4*H*,5*H*-diones (28) in 60-70% yields.<sup>29</sup> This method has been found to have general applicability.

Ar

12 $\frac{\text{Br}_2, \text{CH}}{0^{\circ}\text{C}}$ stir, 1 h		OH O Bi	r Ar <u>pyridine, p</u> benzene reflux, 30		
		27			28
Ar	27, Yield	28, Yield	Ar	27, Yield	28, Yield
C <sub>6</sub> H <sub>5</sub>	95	60	$2-ClC_6H_4$	95	60
$4-NO_2C_6H_4$	100	75	$4\text{-OCH}_3\text{C}_6\text{H}_4$	95	65
$4-CH_3CH_2C_6H_4$	100	60			

The reaction of substituted 3-cinnamoyl-4-hydroxy-6-methyl-2-oxo-2*H*-pyrans (**12**) in  $I_2$ /DMSO provides a facile method for the synthesis of 2-aryl-7-methylpyrano[4,3-*b*]pyran-4*H*,5*H*-diones (**28**).<sup>30</sup> This methodology constitutes a facile, one-step synthesis of **28** as compared to the previously reported procedure.




Oxidative rearrangements are often encountered in the reactions involving I(III) reagents such as  $(PhIOAc)_2$ , and HTIB, particularly in the synthesis of heterocyclic compounds. Reaction of **12** and [hydroxy(tosyloxy)iodo]benzene, HTIB (1.1 equivalent) in dichloromethane gives 3-aryl-7-methylpyrano[4,3-*b*]pyran-4*H*,5*H*-dione (**29**, isoflavone analogues of DHA). This is the first report on the direct conversion of o-hydroxychalcone type compounds into isoflavone analogues.<sup>24</sup>

		o Ar	Ar	Yield
	HTIB,CH <sub>2</sub> Cl <sub>2</sub>		C <sub>6</sub> H <sub>5</sub>	50
12	$rac{\operatorname{IIIIB},\operatorname{CII}_2\operatorname{CI}_2}{\operatorname{or}}$		$4-CH_3C_6H_4$	55
	IBD,CH <sub>3</sub> OH,H <sub>2</sub> SO <sub>4</sub> reflux, 40 h	CH <sub>3</sub> 0 0	$4-OCH_3C_6H_4$	58
	Tentux, 40 II	29	$4-ClC_6H_4$	50
			$2-CH_3C_6H_4$	54
			4-(CH <sub>3</sub> ) <sub>2</sub> CHC <sub>6</sub> H <sub>4</sub>	52

## C) SEVEN-MEMBERED HETEROCYCLIC COMPOUNDS

#### i) Benzothiazepines


1,5-Benzothiazepines have attained much significance due to various biological properties associated with them. 3,4-Dihydro-2-aryl-4-pyronyl-1,5-benzothiazepines (**31**) have been synthesized by the reaction of 2-aminothiophenol (**30**) with the chalcone analogues of DHA (**12**).<sup>31</sup>




Ar	Yield	Ar	Yield
$2-ClC_6H_4$	65	$2-NO_2C_6H_4$	60
$2-OHC_6H_4$	68	$4-NO_2C_6H_4$	61
2,6-(Cl) <sub>2</sub> C <sub>6</sub> H <sub>3</sub>	60	$4-OHC_6H_4$	67

## ii) Benzodiazepines

1,5-Benzodiazepines have found wide applications in medicines and may be considered as one of the most important classes of therapeutic agents associated with diverse biological properties. The ketimine compounds (**33**) have been prepared by treating DHA with *o*-phenylenediamine (**32**) followed by the treatment of the products (**33**) with aromatic aldehydes in ethanol in the presence of a catalytic amount of trifluoroacetic acid. This methodology affords the corresponding 3,4-dihydro-2-pyronyl-1,5-benzodiazepines (**34**).<sup>32</sup>



An alternative and facile method for the synthesis of **34** has also been developed in our laboratory.<sup>10</sup> In this method, the reaction of **32** with 3-cinnamoyl-4-hydroxy-6-methyl-2-oxo-2*H*-pyrans (**12**) in ethanol-acetic acid leads to the formation of 3,4- dihydro-2-pyronyl-1,5-benzodiazepines (**34**) in good yields.



Ar	Yield	Ar	Yield
C <sub>6</sub> H <sub>5</sub>	78	$4-ClC_6H_4$	75
$4-CH_3C_6H_4$	76	$4-OHC_6H_4$	69
$2-OHC_6H_4$	82	$4\text{-OCH}_3\text{C}_6\text{H}_4$	85
4-(CH <sub>3</sub> ) <sub>2</sub> NC <sub>6</sub> H <sub>4</sub>	86	$4-NO_2C_6H_4$	76
2-thienyl	80	$2-NO_2C_6H_4$	83


## SECTION II: REACTIONS THAT INVOLVE PYRONE MOIETY

The reactions included in this Section proceed through the involvment of pyrone moiety of DHA with nucleophiles at C2 and C6 positions resulting in the initial opening of the ring, which in general, is followed by a different mode of cyclization leading to the formation of a new heterocyclic system.


#### A) FIVE-MEMBERED HETEROCYCLIC COMPOUNDS

### i) Pyrazoles and Bipyrazoles

The reactions of DHA with hydrazines have been well investigated, and the intermediates have been isolated and identified. The initial step is the formation of the hydrazones (**9b**), which can be isolated and rearranged to 1-(5-hydroxy-3-methyl-1-substituted pyrazol-4-yl)-1,3-butanediones (**35**).<sup>33</sup> The tautomeric composition of compounds (**35**) has been investigated by a rigorous analysis of NMR spectroscopy and X-Ray crystallography.<sup>8,34</sup> The fragmentation pattern of **35** has been studied under electron-impact and the major processes described.<sup>35</sup>



Condensation of **35** with hydrazines offer a single product which has been identified as the bipyrazolyl (**36A**) and not a mixture of isomers. Out of these two isomers, the correct structure is established with the help of X-Ray crystallography, NMR (<sup>1</sup>H and <sup>13</sup>C) spectroscopy and the solid state (CPMAS) spectrum of the compound.<sup>14,36-40</sup>





36B

R <sup>1</sup>	$\mathbf{R}^2$	Yield	$\mathbb{R}^1$	$\mathbf{R}^2$	Yield
C <sub>6</sub> H <sub>5</sub>	$4-NO_2C_6H_4$	58	$C_6H_5$	1-naphthyl	58
$C_6H_5$	2,4-(NO <sub>2</sub> ) C <sub>6</sub> H <sub>3</sub>	54	$C_6H_5$	4-methylquinolin-2-yl	69
$C_6H_5$	2-pyridyl	60	$C_6H_5$	2-benzothiazolyl	66


In addition to the cyclization reaction leading to the formation of bipyrazoles, and unprecedented reaction of **35** was observed while treating these compounds with hydrazines in ethanol/sodium acetate. In many cases, the reaction led to the cleavage of C—C bond resulting in the formation of two moles of

5-oxo-2-pyrazolines (**39**). The controlling factor for the C—C bond cleavage is the nature of the hydrazine employed in the second step of the reaction and the steric factor also appears to be playing an important role in the bond cleavage.<sup>9,39-42</sup> However, when the reaction is performed in ethanolic HCl, there was exclusive formation of bipyrazolyls. This divergent behavior of compounds (**35**) can be illustrated by treating a typical compound (**37**) ( $\mathbb{R}^1 = 4$ -methyl-6-methoxyquinolin-2-yl), obtained by the rearrangement of **35**, which either undergoes cyclization to the corresponding bipyrazolyl (**38**) on treatment with ethanolic HCl or undergoes C—C bond fission to generates 2 moles of **39**.







When DHA is treated with 4-hydrazino-1-methyl-2(1H)-quinolone (**40**) in DMF at the molar ratio of 1:2, an interesting bipyrazolylquinolone (**41**) is obtained.<sup>43</sup>




Refluxing 1-(5-hydroxy-3-methyl-1-substitutedpyrazol-4-yl)-1,3-butanedione (**35**) in acetic acid in the presence of sulfuric acid leads to the formation of pyranopyrazole (**42**).<sup>44</sup> It is interesting that compounds (**42**) are isomeric to compounds (**10**) and (**11**) described previously. Distinction between these isomeric pyranopyrazoles has been made by NMR (<sup>1</sup>H and <sup>13</sup>C) spectroscopy.<sup>44</sup> Complete analyses have achieved utilizing homonuclear <sup>1</sup>H{<sup>1</sup>H} and two-bond heteronuclear <sup>13</sup>C{<sup>1</sup>H} nuclear Overhauser effects and selective decoupling experiments.



Thiosemicarbazone (**43**) of DHA reacts smoothly with  $\alpha$ -halo ketones to yield the corresponding thiazolylhydrazones (**44**) of DHA, which on refluxing in C<sub>2</sub>H<sub>5</sub>OH-AcOH rearrange to 1-[5-hydroxy-3-methyl-1-(2-thiazolyl)-4-pyrazolyl]-1,3-butanediones (**45**).<sup>45</sup>






2-thienyl	63	61
CH <sub>3</sub>	72	65

The pyrazolylbutane-1,3-diones of the type (**35**) and (**45**) are important precursors for the synthesis of various heterocyclic compounds containing pyrazole moiety. Some of the important examples are presented in the following subsections (**ii**, Pyrazolylisoxazoles and **iii**, Pyrazolylpyrimidines).


## ii) Pyrazolylisoxazoles

Hydrazine hydrate or arylhydrazines react with DHA to give 4-acetoacetyl-3-methylpyrazolin-5-ones (**35**). The conversion of **35** into pyrazoloisoxazoles (**46**) has been achieved on treatment with hydroxylamine.<sup>40</sup>



iii) Pyrazolylpyrimidines


2-Amino-6-methyl-4-(5-hydroxy-3-methyl-1-substituted pyrazol-4-yl)pyrimidines (47) can be synthesized by the condensation of 4-acetoacetyl-5-hydroxy-3-methyl-1*H*-substituted pyrazoles (35) and guanidine carbonate in ethanolic NaOH (40%).<sup>46</sup> Some of these compounds were found to show moderate level of antifungal activity.



R	Yield	R	Yield
C <sub>6</sub> H <sub>5</sub>	72	$4-ClC_6H_4$	68
2-pyridyl	60	2-benzothiazolyl	78
4-methylquinolin-2-yl	69	4-methylthiazol-2-yl	61


## iv) Thiadiazole

Under acylating conditions, DHA thiosemicarbazone (**43**) is transformed into 2-acylamino-5-methyl-1,3,4-thiadiazole (**48**) involving a C—C bond cleavage.<sup>25</sup> The reaction of phenyl thiosemicarbazone (**49**) of DHA with  $RCO_2H/C_2H_5OH$  affords 2-anilino-5-methyl-1,3,4-thiadiazole (**50**).




#### v) Bis-isoxazole

DHA on reaction with two molecules of hydroxylamine leads to the formation of bis-isoxazole (**51**).<sup>47</sup> All of the four electrophilic centers: C2, C4, C6 and the carbonyl of the acetyl chain react in the formation of **51**.



## vi) Benzimidazoles

Condensation of substituted *o*-phenylenediamines (**52**) with DHA (**1**) leads to the formation of 3-[N-(substituted o-aminophenylphenyl)acetimidoyl]-4-hydroxy-6-methyl-2*H*-pyrones (**53**), which on pyrolysis give the corresponding 2-methyl-5-substituted benzimidazoles (**54**).<sup>48,49</sup>




5- CH<sub>3</sub>

H, CH<sub>2</sub>Ph


50-58

#### vii) Pyrazolopyridones

Two series of 3,6-dimethyl-1-phenyl-1*H*-pyrazolo[4,3-*c*]pyridin-4-ones (**55**) and 3,6-dimethyl-1-phenyl-1*H*-pyrazolo[4,3-*c*]pyridine-4-thiones have been prepared from DHA as starting material and evaluated for activity *in vitro*.<sup>50</sup> The activity of the synthesized compounds was compared with that of mirlinone as a reference. Several of the compounds have shown *inotropic* activity more potent than that of mirlinone.




It is relevant to mention that hydrazones (9) are reported to give 1-aminophenyl-3,6-dimethyl-4-oxo-1*H*-phenylpyrazolo[4,3-*c*]pyridines (56) by heating their solution in a mixture of ethanol and acetic acid, are obtained.<sup>51</sup> However reinvestigation of this study by Gelin *et al.* showed the products obtained from this reaction are5-hydroxy-3-methyl-1-phenyl-4-(3-methyl-1-phenylpyrazol-5-yl)pyrazole (bipyrazole, 36A,  $R^1 = R^2 = Ph$ ) rather than 56.<sup>33</sup>




### B) SIX-MEMBERED HETEROCYCLIC COMPOUNDS

#### i) Pyridines


There are many examples of the transformations of DHA (1) into pyridones (59) by treatment with ammonia and primary amines.<sup>52-55</sup> This reaction has been extensively studied and the intermediates (57, 58) have been isolated and identified.<sup>56,57</sup>



2,6-Dimethyl-3,5-dichloro-4-hydroxypyridine (**61**) has been synthesized by a two step reaction.<sup>58</sup> The reaction consists of treating DHA with aq. ammonia thus generating an intermediate product 2,6-dimethyl-4-hydroxypyridine (**60**) which is then chlorinated to give **61**.




The reaction of DHA (1) with 3,4-dihydroisoquinoline (62) offers an illustrative example of the complexities encountered in opening-cyclization sequence.<sup>59,60</sup>




## ii) Pyridones

The reaction between 3-cinnamoyl-4-hydroxy-6-methyl-2-oxo-2*H*-pyrans (**12**) and primary amines results in the formation of substituted 4-pyridones (**65**, R = H, CH<sub>3</sub>). A plausible mechanism for this reaction involves the formation of Schiff's base (**64**) as the intermediate.<sup>61</sup>




iii) Pyranopyridine *N*-oxides

The reaction between the DHA with *N*,*N*-dimethylformamide dimethylacetal gives 4-hydroxy-6-methyl-2-oxo-3-[3-dimethylaminoacryloyl]-2*H*-pyran (**66**). Treatment of **66** with an excess of aq. NH<sub>2</sub>OH.HCl leads to the formation of 4-oxo-5-hydroxylamino-7-methyl-4*H*-pyrano[2,3-*b*]pyridine *N*-oxide (**67**).<sup>23,62,63</sup>




Many interesting versions are encountered in the reaction of hydrazine with *N*-amino heterocycles. Thus, reactions of DHA with *N*-amino-1,2,4-triazole (**68**), hydrazine and *N*-aminopyridinium salts (**71**) produce N,N'-linked bi(heteroaryls) compounds (**69**, **70**, **72**), respectively.<sup>64-66</sup>




v) Pyrimidines

DHA is transformed into pyrimidine derivatives (**73**, **74**) by treatment with thiourea and guanidine.<sup>67</sup> Both these reactions probably proceed through the condensation of initial formed heptane-2,4,6-trione with thiourea and guanidine.



### i) Benzodiazepines


The reaction of *o*-phenylenediamine (OPD) with DHA in different alcohols leads to the formation of 2alkoxycarbonylmethylenebenzodiazepines (**75**) and 4-acetylmethylenebenzodiazepinones (**76**).<sup>49</sup> The alcohols used in this transformation include methyl alcohol, ethyl alcohol, *n*-propyl alcohol, isopropyl alcohol and sterically hindered *t*-butyl alcohol.





#### SECTION III: MISCELLANEOUS REACTIONS


## A) Biogenetic synthesis of phenylisocoumarin

A biogenetic-type synthesis of a dihydroisocoumarin, 3,4-dihydro-8-hydroxy-3-phenylisocoumarin (85) from DHA and *trans*-cinnamaldehyde (77) modeled on the polyketide mode of biosynthesis has been reported by Takeuchi *et al.*<sup>68,69</sup> This is a multistep synthesis and reaction sequence is outlined in **Scheme 1**.










Scheme 1

## B) Formation of macrocyclic imine ligands

A new series of macrocyclic ligands with different ring sizes (14-, 15- and 16-membered) are synthesized from DHA in a two-step reaction process involving Williamson's condensation (**86**) and Schiff base cyclization (**87**) reactions with various diamines such as 1,2- or 1,3-diaminoalkane, carbohydrazide and thiocarbohydrazide.<sup>70</sup> The structures of these macrocycles have been unequivocally established.



## CONCLUSIONS

The above-mentioned examples of the application of DHA and its derivatives for the synthesis of a wide variety of heterocyclic compounds illustrate the versatility of this compound. It may further be mentioned that this inexpensive, crystalline, non-toxic and stable material has lot of unexplored potential for the synthesis of heterocyclic compounds, particularly due to the presence of so many reactive sites in the molecule.

### ACKNOWLEDGEMENT

The work reported here has been supported through **DRDO**, Extramural Basic Research Grant No. ERIP/ER/0103294/M/01 and is subjected to sponsor's disclaimer whose text can be had from the authors. We are grateful to the Mass Spectrometry Facility, University of California, San Francisco which is supported by the Biomedical Research Technology Program, for providing mass spectra.

### REFERENCES

- 1. C. Rivera, E. Pineyro, and F. Giral, *Experientia*, 1976, **32**, 1490.
- 2. H. Ohno, T. Saheki, J. Awaya, A. Nakagawa, and S. Omura, J. Antibiot., 1978, 31, 1116.

- 3. F. Arndt, and P. Nachtwey, Chem Ber., 1954, 57, 1489; (Chem. Abstr., 1925, 19, 286).
- 4. A. B. Steele, A. B. Boese, and M. F. Dull, J. Org. Chem., 1949, 14, 460.
- 5. R. Kaushol, J. Indian Chem. Soc., 1946, 23, 16.
- 6. V. Pechmann, *Ber.*, 1891, **24**, 3600; *Ann.*, 1893, **273**, 194.
- 7. M. M. Manas, and R. Pleixats, 'Advances in Heterocyclic Chemistry' 1992, 53, 1.
- S. P. Singh, M. Grover, L. S. Tarar, J. Elguero, and A. Martinez, *J. Heterocycl. Chem.*, 1990, 27, 865.
- 9. S. P. Singh, D. Kumar, H. Batra, R. Naithani, J. Rozas, and J. Elguero, *Can. J. Chem.*, 2000, **78**, 1109.
- 10. O. Prakash, A. Kumar, Anil Sadana, and S. P. Singh, Synth. Commun. 2002, 32, 2663.
- 11. M. A. Hassan, M. EL-Kady, and A. A. Abd EL-Mohay, *Indian J. Chem.*, 1982, **21B**, 372.
- 12. M. B. Deshmukh and B. S. Shinde, *Indian J. Heterocyclic Chem.*, 1995, 4, 233.
- 13. A. Cantos, P. De March, M. M. Manas, A. Pla, F.S. Ferrando, and A. Virgili, *Chemistry Lett.*, 1986, **3**, 295.
- A. Cantos, P. De March, M. M. Manas, A. Pla, F. S. Ferrando, and A. Virgili, *Bull. Chem. Soc. Jpn.*, 1987, 60, 4425.
- 15. R. H. Wiley, C. H. Jarboe, and H. G. Ellert, J. Am. Chem. Soc., 1955, 77, 5102.
- 16. A. J. Birch, D. W. Cameron, and R. W. Rickards, J. Chem. Soc., 1960, 4395.
- 17. T. M. Harris, C. W. Harris and C. K. Brush, J. Org. Chem., 1970, 35, 1329.
- 18. V. K. Mahesh and R. S. Gupta, *Indian J. Chem.*, 1974, **12B**, 956.
- 19. M. Baboulene, and V. S. A. Lattes, J. Heterocycl. Chem., 1986, 23, 1721.
- M. A. Hassan, M. El-Kady, M. El-Borai, and A. A. Zbd El-Moaty, *Rev. Roum. Chim.*, 1984, 29, 769.
- A. S. Mittra, S. K. Mohanty, R. Sridhar, S. Y. Padmanavan, and S. Rao, *Indian J. Chem.*, 1977, 15B, 1146.
- 22. V. K. Mahesh, C. L. Sharma, S. Vashistha, and R. Sharma, J. Indian Chem. Soc., 1979, 16, 718.
- 23. W. Lowe, J. Heterocycl. Chem., 1977, 14, 931.
- 24. A. Kumar, '*Heterocyclic Compounds*', Ph. D. Thesis, Kurukshetra University, Kurukshetra, 2003.
- 25. L. Somogyi, Ann., 1995, 4, 721.
- 26. M. Siddiq, A. W. Khan, and P. F. Praill, J. Chem. Soc. Pak., 1985, 7, 59.
- V. Y. Sosnovskikh, B. I. Usachev, A. G. Blinov, and M. I. Kodess, *Mendeleev Comm.*, 2001, 1, 36.
- 28. V. K. Mahesh, R. S. Gupta, and R. Sharma, *Indian J. Chem.*, 1979, **17B**, 513.
- 29. M. Siddiq, and Y. Qamar, Indian J. Chem., 1988, 27B, 373.
- 30. O. Prakash, A. Kumar, and S. P. Singh, J. Indian Chem. Soc., 2003, 80, 1.

- 31. N. R. Rao, K. Sucheta, and A. Prashant, *Indian J. Chem.*, 1995, **34B**, 893.
- 32. M. Fodili, M. Amari, B. Kolli, A. Robert, M. B. Floc'h, and P. L. Grel, *Synthesis*, 1999, 811.
- 33. S. Gelin, B. Chantegrel, and A. I. Nadi, J. Org. Chem., 1983, 48, 4078.
- 34. M. J. O Connell, C. G. Ramsay, and P. J. Steel, Aust. J. Chem., 1985, 38, 401.
- 35. S. P. Singh, R. K. Vaid, P. Diwakar, and L. Singh, Org. Mass Spectrom., 1988, 23, 10.
- S. P. Singh, D. Kumar, A. Martinez, A. Fruchier, J. Elguero, M. R. Martinez, J. S. Carrio, and A. Virgili, *Tetrahedron*, 1995, 51, 4891.
- 37. A. S. Afridi, A. R. Katritzky, and C. A. Ramsden, J. Chem. Soc., Perkin Trans. I, 1977, 1, 1428.
- 38. B. Djerrari, E. Essassi, and J. Fifani, Bull. Soc. Chim. Fr., 1991, 521.
- 39. S. P. Singh, L. S. Tarar, and D. Kumar, *Indian J. Heterocycl. Chem.*, 1993, 3, 5.
- 40. A. Bendaas, M. Hamdi, and N. Sellier, J. Heterocycl. Chem., 1999, 36, 1291.
- 41. S. P. Singh, O. Prakash, and R. K. Vaid, *Indian J. Chem.*, 1984, 23B, 191.
- 42. R. Naithani, '*Heterocyclic Compounds*', Ph. D. Thesis, Kurukshetra University, Kurukshetra, 2000.
- 43. M. Abass, Synth. Commun., 2000, **30**, 2735.
- 44. S. P. Singh, C. P. Kaushik, and D. Kumar, *Indian J. Chem.*, 1999, **38B**, 1377.
- 45. S.P. Singh, L.S. Tarar and D. Kumar, *Synth. Commun.* 1993, 23, 1855.
- 46. H. Batra, '*Heterocyclic Compounds*', Ph. D. Thesis, Kurukshetra University, Kurukshetra, 1998.
- 47. A. Inoue and S. Iguchi, *Chem. Pharm. Bull.*, 1964, **12**, 381.
- 48. M. A. Qayyoom, P. Hanumanthu, and C. V. Ratnam, *Indian J. Chem.*, 1982, **21B**, 883.
- 49. M. El Abbassi, B. Djerrari, E. M. Essassi, and J. Fifani, *Tetrahedron Lett.*, 1989, **30**, 7069.
- 50. K. Ogawa and K. Miyoshi, J. Pharm. Sci., 1992, 81, 581.
- 51. V. K. Mahesh and R. S. Gupta, *Indian J. Chem.*, 1974, **12B**, 570.
- 52. L. Haitinger, Ber., 1885, 18, 452.
- 53. C. S. Wang, J. P. Easterly, and N. E. Skelly, *Tetrahedron*, 1971, 27, 2581.
- 54. M. P. Sammes and K. L. Yip, J. Chem. Soc., Perkin Trans. I, 1978, 1373.
- 55. H. Takalo, P. Pasanen, and J. Kankare, Acta Chem. Scand. Ser. B., 1988, 42B, 373.
- 56. D. Cook, Can. J. Chem., 1963, **41**, 1435.
- 57. S. Garratt, J. Org. Chem., 1963, 28, 1886.
- 58. Z. Zhang, L. M. Hu, J. H. Lu, H. Chang, and Z. B. Chen, *Peop. Rep. China. Jingxi Huagong*, 2000, **17**, 149.
- 59. A. A. Akhrem, A. M. Moiseenkov, and V. A. Krivoruchko, *Izv. Akad. Nauk SSSR, Ser. Khim.*, 1971, 1126 (*Chem. Abstr.*, 1971, **75**, 88457).
- 60. A. A. Akhrem, A. M. Moiseenkov, and V. A. Krivoruchko, *Izv. Akad. Nauk SSSR, Ser. Khim.*, 1973, 1302 (*Chem. Abstr.*, 1973, **79**, 126360).

- 61. M. Iqbal, M. A. Munawar, and M. Siddiq, J. Chem. Soc. Pak., 1989, 11, 238.
- 62. W. Lowe, Arch. Pharm., 1978, **311**, 414.
- 63. W. Lowe, B. Braun, and B. Muller, J. Heterocycl. Chem., 1994, **31**, 1577.
- 64. M. P. Sammes, H. K. Wahi, and A. R. Katritzky, J. Chem. Soc., Perkin Trans. I, 1977, 327.
- 65. A. R. Katritzky, M. H. Ibrahim, J. Y. Valnot, and M. P. Sammes, *J. Chem. Res. Synop.*, 1981, **3**, 70.
- 66. A. S. Afridi, J. Chem. Soc. Pak., 1982, 4, 55.
- 67. M. Hubert-Habart, C. Pene, and R. Royer, *Chim. Ther.*, 1973, **8**, 194.
- 68. N. Takeuchi, M. Murase, K. Ochi, and S. Tobinaga, *Chem. Pharm. Bull.*, 1980, 28, 3013.
- 69. N. Takeuchi, M. Murase, K. Ochi, and S. Tobinaga, J. Chem. Soc., Chem. Commun., 1976, 20, 820.
- 70. G. S. R. Reddy and N. R. Rao, *Indian J. Chem.*, 1994, **33B**, 113.